1.14
-0.05(-4.20%)
Currency In GBp
Address
MediCity
Nottingham, NG90 6BH
United Kingdom of Great Britain and Northern Ireland
Phone
44 1157 840 500
Website
Sector
Healthcare
Industry
Biotechnology
Employees
40
First IPO Date
May 18, 2016
| Name | Title | Pay | Year Born |
| Mr. Martin John Gouldstone | Chief Executive Officer & Director | 255,000 | 1966 |
| Mr. Martin Hudson | Chief Financial Officer | 0 | N/A |
| Ms. Cléa Rosenfeld | Head of Investor Relations | 0 | N/A |
| Dr. Petra Budde | Chief Scientific Officer | 0 | N/A |
Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a immunodiagnostic test for detecting and identifying lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.
